 |
 |
 |
 |
 |
 |
 |
|
|||||||
|
Select Publications
Bonomi PD et al. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 2007;13(15 Pt 2):s4606-12. Abstract
Fong T et al. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 2008;3(3):303-10. Abstract
Hanauske AR et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007;25(5):417-23.
Abstract
Herbst RS et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment
of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25(30):4743-50. Abstract
Ramalingam SS et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26(1):60-5. Abstract
Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract
Scagliotti G et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Proc IASLC 2007;Abstract PRS-03.
Seiwert TY et al. A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer. Proc ASCO 2005;Abstract 7062.
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Mark G Kris, MD
- Select publications
Roman Perez-Soler, MD
- Select publications
Julie R Brahmer, MD
- Select publications
Philip Bonomi, MD
- Select publications
Lung Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
